ArticleImmunogenetics1996
A peptide encoded by the human MAGE3 gene and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3.
Article in Immunogenetics, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 104 citations in OpenAlex.
- Therapeutic Cancer Vaccines-Antigen Discovery and Adjuvant Delivery Platforms.Pharmaceutics · 2022Review
- Immune targets and neoantigens for cancer immunotherapy and precision medicine.Cell research · 2017Review
- Immunotherapy in gastric cancer.World journal of gastroenterology · 2014Review
- Enhancing cancer immunotherapy by intracellular delivery of cell-penetrating peptides and stimulation of pattern-recognition receptor signaling.Advances in immunology · 2012Review
- Review
- Insights into the processing of MHC class I ligands gained from the study of human tumor epitopes.Cellular and molecular life sciences : CMLS · 2011Review
- Use of dentritic cells pulsed with HLA-A2-restricted MAGE-A1 peptide to generate cytotoxic T lymphocytes against malignant glioma.Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban · 2010Article
- A new LAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-A68 tumors.Cancer immunology, immunotherapy : CII · 2006Article
- HLA class I and class II frequencies in patients with cutaneous malignant melanoma from southeastern Spain: the role of HLA-C in disease prognosis.Immunogenetics · 2006Article
- Lessons to be learned from primary renal cell carcinomas: novel tumor antigens and HLA ligands for immunotherapy.Cancer immunology, immunotherapy : CII · 2005Article
- A naturally selected dimorphism within the HLA-B44 supertype alters class I structure, peptide repertoire, and T cell recognition.The Journal of experimental medicine · 2003Article
- Identification of a polymorphic gene, BCL2A1, encoding two novel hematopoietic lineage-specific minor histocompatibility antigens.The Journal of experimental medicine · 2003Article
- Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis.The Journal of experimental medicine · 2001Article
- Modulation of proteasomal activity required for the generation of a cytotoxic T lymphocyte-defined peptide derived from the tumor antigen MAGE-3.The Journal of experimental medicine · 1999Article
- Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes.The Journal of experimental medicine · 1999Article
- Molecular cancer vaccines: Tumor therapy using antigen-specific immunizations.Pathology oncology research : POR · 1997Article
- Human tumor antigens recognized by T-cells.Immunologic research · 1997Review
- Cytolytic T lymphocyte responses of cancer patients to tumor-associated antigens.Springer seminars in immunopathology · 1996Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 3 countries.
Funding
Abstract
The human MAGE3 gene is expressed in a significant proportion of tumors of various histological types, but is silent in normal adult tissues other than testis and placenta. Antigens encoded by MAGE3 may therefore be useful targets for specific antitumor immunization. Two antigenic peptides encoded by the MAGE3 gene have been reported previously. One is presented to cytolytic T lymphocytes (CTL) by HLA-A1, the other by HLA-A2 molecules. Here we show that MAGE3 also codes for a peptide that is presented to CTL by HLA-B44. MAGE3 peptides containing the HLA-B44 peptide binding motif were synthesized. Peptide MEVDPIGHLY, which showed the strongest binding to HLA-B44, was used to stimulate blood T lymphocytes from normal HLA-B44 donors. CTL clones were obtained that recognized not only HLA-B44 cells sensitized with the peptide, but also HLA-B44 tumor cell lines expressing MAGE3. The proportion of metastatic melanomas expressing the MAGE3/HLA-B44 antigen should amount to approximately 17% in the Caucasian population, since 24% of individuals carry the HLA-B44 allele and 76% of these tumors express MAGE3.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.